Carlota Recio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6621917/publications.pdf Version: 2024-02-01



CARLOTA RECIO

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Activation of the Immune-Metabolic Receptor GPR84 Enhances Inflammation and Phagocytosis in Macrophages. Frontiers in Immunology, 2018, 9, 1419. | 2.2 | 110 |
| 2 | The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease. Frontiers in Pharmacology, 2016, 7, 526. | 1.6 | 77 |
| 3 | Targeting HSP90 Ameliorates Nephropathy and Atherosclerosis Through Suppression of NF-κB and STAT Signaling Pathways in Diabetic Mice. Diabetes, 2015, 64, 3600-3613. | 0.3 | 64 |
| 4 | The Mevalonate Pathway, a Metabolic Target in Cancer Therapy. Frontiers in Oncology, 2021, 11, 626971. | 1.3 | 64 |
| 5 | Suppressor of Cytokine Signaling 1–Derived Peptide Inhibits Janus Kinase/Signal Transducers and Activators of Transcription Pathway and Improves Inflammation and Atherosclerosis in Diabetic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1953-1960. | 1.1 | 59 |
| 6 | Nrf2 Activation Provides Atheroprotection in Diabetic Mice Through Concerted Upregulation of Antioxidant, Anti-inflammatory, and Autophagy Mechanisms. Frontiers in Pharmacology, 2018, 9, 819. | 1.6 | 59 |
| 7 | Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 575-585. | 3.0 | 54 |
| 8 | Peptide Inhibitor of NF-κB Translocation Ameliorates Experimental Atherosclerosis. American Journal of Pathology, 2013, 182, 1910-1921. | 1.9 | 52 |
| 9 | Acute exposure to apolipoprotein A1 inhibits macrophage chemotaxis in vitro and monocyte recruitment in vivo. ELife, 2016, 5, . | 2.8 | 50 |
| 10 | SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition. Laboratory Investigation, 2018, 98, 1276-1290. | 1.7 | 45 |
| 11 | Peptide-based inhibition of lκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes. Diabetologia, 2015, 58, 1656-1667. | 2.9 | 40 |
| 12 | FcÎ ³ Receptor Deficiency Attenuates Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1518-1527. | 3.0 | 37 |
| 13 | Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice. Basic Research in Cardiology, 2015, 110, 8. | 2.5 | 28 |
| 14 | A Biased Agonist at Immunometabolic Receptor GPR84 Causes Distinct Functional Effects in Macrophages. ACS Chemical Biology, 2019, 14, 2055-2064. | 1.6 | 27 |
| 15 | Gene Deficiency in Activating Fcl ³ Receptors Influences the Macrophage Phenotypic Balance and Reduces Atherosclerosis in Mice. PLoS ONE, 2013, 8, e66754. | 1.1 | 25 |
| 16 | Cannabinoid Receptor 2 Modulates Neutrophil Recruitment in a Murine Model of Endotoxemia. Mediators of Inflammation, 2017, 2017, 1-15. | 1.4 | 24 |
| 17 | Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology. Oncogene, 2019, 38, 4657-4668. | 2.6 | 24 |
| 18 | Interplay between HSP90 and Nrf2 pathways in diabetes-associated atherosclerosis. ClÃnica E Investigación En Arteriosclerosis, 2017, 29, 51-59. | 0.4 | 21 |

CARLOTA RECIO

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Absence of the Non-Signalling Chemerin Receptor CCRL2 Exacerbates Acute Inflammatory Responses In Vivo. Frontiers in Immunology, 2017, 8, 1621. | 2.2 | 18 |
| 20 | Characterisation of endogenous Galectin-1 and -9 expression in monocyte and macrophage subsets under resting and inflammatory conditions. Biomedicine and Pharmacotherapy, 2020, 130, 110595. | 2.5 | 17 |
| 21 | The Role of Metabolite-Sensing G Protein-Coupled Receptors in Inflammation and Metabolic Disease. Antioxidants and Redox Signaling, 2018, 29, 237-256. | 2.5 | 13 |
| 22 | In Vitro Migration Assays. Methods in Molecular Biology, 2018, 1784, 197-214. | 0.4 | 4 |
| 23 | JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. Biomedicine and Pharmacotherapy, 2021, 144, 112330. | 2.5 | 4 |
| 24 | Interplay between HSP90 and Nrf2 pathways in diabetes-associated atherosclerosis. ClÃnica E Investigación En Arteriosclerosis (English Edition), 2017, 29, 51-59. | 0.1 | 0 |